PHASE I STUDY OF ADOPTIVE T CELL THERAPY FOLLOWING HER2-PULSED DENDRITIC CELL VACCINE AND PEPINEMAB/TRASTUZUMAB IN PATIENTS WITH METASTATIC HER2-POSITIVE BREAST CANCER (MBC)

被引：0

作者：

Han, Hyo ^{[1
]}

Evans, Elizabeth ^{[2
]}

Fisher, Terrence ^{[2
]}

Soliman, Hatem ^{[1
]}

Khong, Hung ^{[1
]}

Soyano, Aixa ^{[1
]}

Costa, Ricardo ^{[1
]}

Loftus, Loretta ^{[1
]}

Lee, Kimberley ^{[1
]}

Armaghani, Avan ^{[1
]}

Liu, Hien ^{[1
]}

Locke, Frederick ^{[1
]}

Shrewsbury, Alexandria ^{[1
]}

Malka, Jessica ^{[1
]}

Karyampudi, Lavakumar ^{[1
]}

Zauderer, Maurice ^{[2
]}

Czerniecki, Brian ^{[1
]}

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[2] Vaccinex Inc, Rochester, NY USA

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷

关键词：

D O I：

10.1136/jitc-2022-SITC2022.0645

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

645

引用

页码：A676 / A676

页数：1

共 50 条

[11] Trastuzumab Deruxtecan in HER2-positive metastatic Breast Cancer
Lorenz, Judith
GEBURTSHILFE UND FRAUENHEILKUNDE, 2024, 84 (08) : 670 - 670
[12] Trastuzumab as Single Agent Therapy for HER2-Positive Metastatic Breast Cancer
Rastogi, Priya
Davidson, Nancy E.
ONKOLOGIE, 2010, 33 (8-9): : 420 - 421
[13] Retreatment with trastuzumab in Her2-positive metastatic breast cancer patients: a clinical study
F Carabantes-Ocón
E Saez-Lara
L Burgos-Garcia
E Villar-Chamorro
A Casaus-Hazañas
S Luna
C Martínez
Breast Cancer Research, 9
[14] Retreatment with trastuzumab in Her2-positive metastatic breast cancer patients:: a clinical study
Carabantes-Ocon, F.
Saez-Lara, E.
Burgos-Garcia, L.
Villar-Chamorro, E.
Casaus-Hazanas, A.
Luna, S.
Martinez, C.
BREAST CANCER RESEARCH, 2007, 9 (01)
[15] Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer
Ring, Alistair
Wheatley, Duncan
Hatcher, Helen
Laing, Robert
Plummer, Ruth
Uttenreuther-Fischer, Martina
Temple, Graham
Pelling, Katy
Schnell, David
CLINICAL CANCER RESEARCH, 2015, 21 (12) : 2737 - 2744
[16] A phase II study of weekly vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer
Lucas Bayo-Calero, Juan
Mayordomo, Jose I.
Salnchez-Rovira, Pedro
Perez-Carrion, Ramon
Illaramendi, Jose J.
Garcia-bueno, Jose M.
Gonzalez-Flores, Encarnacion
Crespo, Carmen
Ramos-Vazquez, Manuel
Garcia-Palomo, Andres
Ruiz-Borrego, Manuel
de la Haba, Juan
Gomez-Bernal, Amalia
Yubero-Esteban, Alfonso
CLINICAL BREAST CANCER, 2008, 8 (03) : 264 - 268
[17] Continued trastuzumab therapy for patients with HER2-positive breast cancer
Haslbauer, F.
EJC SUPPLEMENTS, 2008, 6 (07): : 221 - 221
[18] A phase 2 study of poziotinib in patients with HER2-positive metastatic breast cancer (MBC) who have received prior HER2 regimens for MBC
Lathrop, K.
Lucas, J.
Vacirca, J. L.
Bhat, G.
Choi, M. R.
Naughton, M.
CANCER RESEARCH, 2017, 77
[19] Radiosensitization of HER2-positive breast cancer cell lines with trastuzumab
Alanyali, Senem Demirci
Bozkurt, Emir
Alanyali, Hilmi
Karaca, Burcak
Uslu, Ruchan
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[20] MOLECULAR PREDICTORS FOR PRIMARY RESISTANCE TO TRASTUZUMAB IN HER2-POSITIVE METASTATIC BREAST CANCER (MBC) PATIENTS (PTS)
Landi, L.
Marchetti, A.
Fabi, A.
Mottolese, M.
Destro, A.
Fabiani, S.
Cappuzzo, F.
Varella-Garcia, M.
Roncalli, M.
ANNALS OF ONCOLOGY, 2011, 22 : 39 - 39

← 1 2 3 4 5 →